Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Verträglichkeit (9 Abbildungen)
Übersicht


Zum ersten Bild Abb. 2: Telmisartan - Placebo - Verträglichkeit Abb. 3: Telmisartan - Verträglichkeit Abb. 4: Telmisartan - HCTZ - Verträglichkeit Abb. 5: Verträglichkeitsprofil Abb. 6: Verträglichkeitsprofil Abb. 7: Verträglichkeitsprofil Aktuelles Bild - Abb. 8: HCTZ - Hypokaliämische Einflüsse Abb. 9: Verträglichkeit
Abbildung 8: HCTZ - Hypokaliämische Einflüsse
Thiazide therapy can cause hypokalaemia, which can, potentially, trigger adverse cardiac events.1,2 Reported here are selected arms from an 8-week, 4 x 5 factorial, multicentre, double-blind, placebo-controlled, dose-finding study conducted in 818 patients with mild-to-moderate hypertension.3 Patients were randomized to telmisartan 20 mg, 40 mg, 80 mg or 160 mg alone or in combination with HCTZ 6.25 mg, 12.5 mg, or 25 mg, giving a total of 20 treatment groups. HCTZ caused a dose-related decrease in serum potassium. Combination with telmisartan tended to offset the effects of HCTZ on serum potassium levels. 1. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977; 12: 297–303. 2. Siscovick D, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852–1857. 3. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23: 833–850.
 
HCTZ - Hypokaliämische Einflüsse
Vorheriges Bild Nächstes Bild   


Abbildung 8: HCTZ - Hypokaliämische Einflüsse
Thiazide therapy can cause hypokalaemia, which can, potentially, trigger adverse cardiac events.1,2 Reported here are selected arms from an 8-week, 4 x 5 factorial, multicentre, double-blind, placebo-controlled, dose-finding study conducted in 818 patients with mild-to-moderate hypertension.3 Patients were randomized to telmisartan 20 mg, 40 mg, 80 mg or 160 mg alone or in combination with HCTZ 6.25 mg, 12.5 mg, or 25 mg, giving a total of 20 treatment groups. HCTZ caused a dose-related decrease in serum potassium. Combination with telmisartan tended to offset the effects of HCTZ on serum potassium levels. 1. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977; 12: 297–303. 2. Siscovick D, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852–1857. 3. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23: 833–850.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung